# <u>LETTERS</u>

# Synthesis of the Natural Product Marthiapeptide A

Yuqi Zhang,<sup>†</sup> Md. Amirul Islam,<sup>†</sup> and Shelli R. McAlpine<sup>\*,†</sup>

<sup>†</sup>School of Chemistry, The University of New South Wales, Gate 2 High Street, Sydney 2052, Australia

Supporting Information



**ABSTRACT:** The first total synthesis of marthiapeptide A is reported. Two synthetic procedures are described: the first, which was unsuccessful, attempts to close the ring at position I, and the second, which was successful, closes the ring at position II. It appears that the first route was unsuccessful because it required cyclization next to the rigid thiazole moiety, whereas the second route closed next to the more flexible thiazoline ring.

L inked azoles are unique substructures that are present in many natural products. Over the past two decades, there has been a surge in the discovery of natural product compounds that contain linked azoles, where many of these compounds are now candidates for drug development.<sup>1</sup> Urukthapelstatin A (Ustat A) (Figure 1) is a natural product isolated from marine



Figure 1. Structures of Ustat A, HXDV, and MTA (1).

bacteria, and it has a bisoxazole and a bisthiazole moiety located within the macrocycle. It shows potent anticancer activity against a panel of human cancer cell lines, with an average  $IC_{50}$ value of 12 nM.<sup>2,3</sup> **HXDV** (Figure 1) is a synthetic derivative of telomestatin, and it has two linked trioxazoles within its macrocyclic backbone. **HXDV** exhibits antiproliferative and apoptotic activity by stabilizing the G-quadruplex of DNA that is formed during replication.<sup>4,5</sup> Marthiapeptide A (**MTA**) (Figure 1) is another potent natural product that contains a linked trithiazole–thiazoline system and cytotoxicity with an  $IC_{50} = ~380-520$  nM against a panel of cancer cell lines.<sup>6</sup> We previously reported the first synthesis of **Ustat** A<sup>3</sup> and the synthesis of trioxazole fragments of **HXDV**.<sup>7</sup> Herein we report the synthesis of **MTA**. MTA was isolated by Zhou and co-workers in 2012.<sup>6</sup> It is a cyclic peptide that consists of three consecutive thiazoles and thiazoline and was isolated from a south China sea derived strain *Marinactinospora thermotolerans*. This natural product exhibits significant cytotoxicity against a panel of human cancer cell lines with  $GI_{50}$  value ranges from 0.38 to 0.52  $\mu$ M. D-Alanine, L-isoleucine, and D-phenylalanine connected to a trithiazole thiazoline system makes up the complex structure shown in Figure 1. Outlined is our unsuccessful initial route as well as the successful final route for completing the synthesis of MTA.

Our initial strategy (A) involved a macrocyclization of the linear precursor via a peptide coupling reaction between the amine on the alanine residue and the carboxylic acid end of isoleucine (position I, Scheme 1). However, the cyclization was not successful, which was attributed to the closing point being too close to the rigid heterocyclic thiazole moiety. Our second strategy (B) involved closing between the thiazoline and peptide (position II Scheme 1). This approach worked, and although it was not high yielding, we believe that this successful cyclization can be attributed to the flexibility of the thiazoline, which allows a connection between the molecule's head and tail.

Cyclization for the initial strategy involved the synthesis of 2 (dipeptide) and 3 (trithiazole ester) and coupling at position II to give the linear molecule shown in route A. Cyclization then occurred at position I. The successful strategy involved coupling 2 and 3 at position I first and then cyclizing at position II. Generation of 3 was accomplished by sequentially

Received: September 6, 2015

Scheme 1. Retrosynthetic Scheme for Synthesizing Marthiapeptide<sup>*a*</sup>



synthesizing thiazoles using a modified Hantzsch synthesis, which condensed ethyl 2-bromopyruvate and a thioamide. The synthesis of dipeptide 2 was accomplished via standard peptide-coupling conditions between Boc-NH-D-Phe-OH carboxylic acid with H<sub>2</sub>N-Ile-OMe amine.

The synthesis of 3 was completed using our previously reported procedure.<sup>7</sup> Specifically, BocHN-D-Ala-OH underwent 12 steps, via sequential thiazole Hantzsch synthesis, to generate 3 in an overall yield of 20%. The first strategy started from 3, where the trithiazole ester was sonicated with a solution of ammonium hydroxide (Scheme 2) generating amide 4. Dehydration of the amide to the nitrile using trifluoroacetic anhydride (TFAA) in the presence of N,N-diisopropylethylamine (DIPEA) and CH<sub>2</sub>Cl<sub>2</sub> produced the nitrile 5. The crude material underwent flash column chromatography to afford pure 5 in an 80% yield. Condensation of the nitrile with Lcysteine was then carried out using NaHCO<sub>3</sub> in the presence of phosphate buffer (pH = 5.95) at 70 °C to furnish thiazoline 6. Amine deprotection of 2 was achieved using trifluoroacetic acid (TFA) generating 7. Coupling crude 7 to free acid thiazoline 6 using coupling agent 1-bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) in the presence of DIPEA generated 8. Ester hydrolysis of 8 produced crude free acid 9, where the crude was treated with TFA to remove the Boc protecting group generating 10. Subsequent cyclization of the double deprotected linear precursor 10 using HATU and 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) in the presence of DIPEA failed to generate compound 1.

Scheme 2. Initial Synthetic Route (A) Was Unsuccessful at Producing the Desired Natural Product 1



We hypothesized that the ring failed to close at position I because the ring-closure site was too close to the rigid thiazole moieties. The proximity of the four relatively rigid structures to the ring-closing site likely made it impossible to connect the head and tail end of the compound.

Similar to the initial route, the final route (B) was also initiated starting with 3, whereupon Boc removal produced 11 (Scheme 3). Conversion of 2 to the free acid using  $LiOH \cdot H_2O$ produced 12 in preparation for coupling to 11. Using HATU in the presence of DIPEA, 11 was coupled to 12 generating 13 in a 72% yield. Subsequent conversion to the amide 14 using ammonium hydroxide was accomplished using sonication over 48 h (Scheme 3). The larger structure 13 converted more slowly to the amide 14 than the smaller structure (3 to amide 4, Scheme 2). Dehydration of the amide 14 to the nitrile 15 was produced in a lower yield than the corresponding dehydration of the smaller molecule used in the initial route (Scheme 2, structure 4 to 5). Indeed, the conditions for nitrile 15 formation required modification, whereupon the optimal yield was produced when using molecular sieves. Condensing Lcysteine with 15 in the presence of sodium bicarbonate in a phosphate buffer generated linear precursor 16. Amine deprotection using TFA produced the linear precursor. Cyclization was accomplished using a syringe pump, which added the compound into a cocktail of three coupling agents: HATU, DMTMM, and O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) in the presence of DIPEA.

Scheme 3. Final Synthetic Route (B) Successfully Produced the Desired Natural Product 1



Upon disappearance of the starting material, as observed when monitoring by LCMS, the reaction was washed with an acid and then base in order to remove coupling agent side products. The resulting crude material was purified via flash column chromatography on silica gel. The relatively product was isolated from the column, and a second purification was done using reverse phase HPLC. Final purity was verified by evaluating the compound using two different conditions on the LCMS (Supporting Information) and co-injecting it with the natural product kindly provided by the original isolation team<sup>6</sup> using these two systems. The LCMS coinjection data show that the synthetic product was identical in retention time and mass to the natural product. The HRMS also indicated that our sample was pure, where the calculated exact mass and observed mass were 688.1269 and 688.1260 respectively, (Supporting Information). <sup>1</sup>H and 2-D NMR were assigned (Supporting Information), and by use of 2-D NMR a carbon spectral shift difference was completed between the synthetic and the natural product (Supporting Information). The carbon shifts were essentially identical between the natural product and the synthetic compound 1 (with a maximum of 1 ppm difference between assigned carbons).

In conclusion, we have described two synthetic routes where one produced the natural product marthiapeptide A. The successful ring closing occurred next to the more flexible thiazoline versus the unsuccessful ring closing attempted next to the more rigid thiazole. Future analogues might be generated most effectively by cyclizing between the phenylalanine and the isoleucine residue because this is likely the most flexible position around the macrocyclic backbone.

#### ASSOCIATED CONTENT

## Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.or-glett.5b02574.

Synthetic and biological procedures, characterization data, and biological data (PDF)

# AUTHOR INFORMATION

#### **Corresponding Author**

\*E-mail: s.mcalpine@unsw.edu.au.

## Notes

The authors declare no competing financial interest.

# ACKNOWLEDGMENTS

This research was funded by an NHMRC grant (No. APP1043561) which provided a Ph.D. scholarship to A.I. We also thank the University of New South Wales for a tuition fee waiver for A.I. We acknowledge the kind donation of the natural product from Dr. Jianhua Ju, Huang Hongbo, and co-workers,<sup>6</sup> South China Sea Institute of Oceanology, Chinese Academy of Sciences.

# REFERENCES

(1) (a) Riego, E.; Hernández, D.; Albericio, F.; Álvarez, M. Synthesis 2005, 2005, 1907–1922. (b) Baumann, M.; Baxendale, I. R.; Ley, S. V.; Nikbin, N. Beilstein J. Org. Chem. 2011, 7, 442–495. (c) Duchler, M. J. Drug Target. 2012, 20, 389–400. (d) Boger, D. L.; Lee, J. K. J. Org. Chem. 2000, 65, 5996–6000. (e) Dang, Q.; Liu, Y.; Cashion, D. K.; Kasibhatla, S. R.; Jiang, T.; Taplin, F.; Jacintho, J. D.; Li, H.; Sun, Z.; Fan, Y.; DaRe, J.; Tian, F.; Li, W.; Gibson, T.; Lemus, R.; van Poelje, P. D.; Potter, S. C.; Erion, M. D. J. Med. Chem. 2011, 54, 153– 165. (f) Rzuczek, S. G.; Pilch, D. S.; Liu, A.; LaVoie, E. J.; Rice, J. E. J. Med. Chem. 2010, 53, 3632–3644.

(2) (a) Matsuo, y.; Kanoh, K.; Imagawa, H.; Adachi, K.; Nishizawa, M.; Shizuri, Y. J. Antibiot. 2007, 60, 256–260. (b) Kim, S.-J.; Lin, C.-C.; Pan, C.-M.; Rananaware, D. P.; Ramsey, D. M.; McAlpine, S. R. MedChemComm 2013, 4, 406–410.

(3) Lin, C.-C.; Tantisantisom, W.; McAlpine, S. R. Org. Lett. 2013, 15, 3574–3577.

(4) Tsai, Y.-C.; Lin, C.-P.; Lin, R.-K.; Kerrigan, J. E.; Rzuczek, S. G.; LaVoie, E. J.; Rice, J. E.; Pilch, D. S.; Lyu, Y. L.; Liu, L. F. *J. Biol. Chem.* **2009**, 284, 22535–22543.

(5) Satyanarayana, M.; LaVoie, E. J.; Pilch, D. S.; Liu, A.; Liu, L. F.; Rice, J. E. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 3802–3804.

(6) Zhou, X.; Huang, H.; Chen, Y.; Tan, J.; Song, Y.; Zou, J.; Tian, X.; Hua, Y.; Ju, J. J. Nat. Prod. **2012**, 75, 2251–2255.

(7) Islam, A.; Zhang, Y.; Wang, Y.; McAlpine, S. R. *MedChemComm* **2015**, *6*, 300–305.